Elsevier

Vaccine

Volume 32, Issue 52, 12 December 2014, Pages 7043-7046
Vaccine

Short communication
Varicella vaccination coverage inverse correlation with varicella hospitalizations in Spain

https://doi.org/10.1016/j.vaccine.2014.10.076Get rights and content

Abstract

Varicella vaccines available in Spain were marketed in 1998 and 2003 for non-routine use. Since 2006 some regions included universal varicella vaccination in their regional routine vaccination programs at 15–18 months of age. Regions without universal vaccination in toddlers, but instead with the strategy of vaccinating susceptible adolescents, reached different varicella vaccination coverage through private market.

This study shows the correlation between severe varicella zoster virus infections requiring hospitalization and the varicella vaccination coverage by region.

A total of 3009 hospital discharges related to varicella were reported in 2009–2010. The overall annual rate of hospitalization was 3.27 cases per 100,000. In children younger than 5 years old varicella hospitalization rate was 30.73 cases per 100,000.

Varicella related hospitalizations were significantly lower in the regions with universal vaccination. In those regions without universal vaccination at 15–18 months of age, those with higher coverage in private market showed lower hospitalization rates.

Section snippets

Conflict of interest statement

MSM is employee of Sanofi Pasteur, MSD, Spain. RGP and AGM have received support for grants and travel grants for Scientific Congress from Sanofi Pasteur, MSD and GSK.

Acknowledgement

The Subdirección General del Instituto de Información Sanitaria provided with the information in which this study is based.

References (20)

There are more references available in the full text version of this article.

Cited by (16)

  • Impact of six years of routine varicella vaccination on the disease-related hospitalizations at Minas Gerais, Brazil

    2022, Vaccine
    Citation Excerpt :

    In this study, it was possible to ascertain that a 20% increase in vaccine coverage is able to reduce the number of varicella cases by up to 30% [25]. In Spain, an inverse relationship was established between the number of hospitalizations and the vaccine coverage rate [26]. The relevance of this relationship may help to clarify the peak in hospital admissions that occurred in 2017, when vaccination coverage rates lowered to under 80%.

  • Varicella vaccination as useful strategy for reducing the risk of varicella-related hospitalizations in both vaccinated and unvaccinated cohorts (Italy, 2003–2018)

    2020, Vaccine
    Citation Excerpt :

    These estimates were subjected to a significant reduction after the introduction of the varicella vaccination, with a decrease higher than 80% during the first five years. Similarly, decreasing percentages were found in other European countries, as Germany (−77.6% in children <5 years, VC = 53%) [22] or Spain (−83.5% in children <5 years, VC = 32%) [23] or in non-European countries such as Australia (−76.8% in children 1–4 years, VC = 90%) [24], Canada (−93.0% in children 1–4 years, VC = 93%) [25], and Uruguay (−94% in children 1–4 years, VC = 96%) [26]. We observed that hospitalization rates consistently decreased two or more years after the introduction of the vaccination and this finding would explain why some countries, with short observation period after vaccine implementation (2–4 years) and low vaccination coverage, could observe only smaller reductions.

  • Seeking the optimal schedule for chickenpox vaccination in Canada: Using an agent-based model to explore the impact of dose timing, coverage and waning of immunity on disease outcomes

    2020, Vaccine
    Citation Excerpt :

    Chickenpox vaccine timing is only one of a variety of other unknowns that may impact chickenpox disease outcomes. For instance, coverage rates vary by region, and it would be valuable to understand how this impacts herd immunity and population-level disease outcomes [9]. Moreover, there is substantial variation in the primary chickenpox vaccine failure estimates in the literature, as well as in estimates of the rate at which vaccine immunity wanes [10,11].

  • Evaluation of impact of one dose varicella vaccine on the incidence of chickenpox in Argentina

    2020, Vaccine
    Citation Excerpt :

    However, these studies are based on theoretical models, unlike this study, which incorporates varicella cases informed to the monitoring system [54]. It is expected that costs decrease as incidence rates and hospitalization decrease, as it occurs in other countries [55–57]. We would like to mention some limitations of the presented study.

  • Early impact of universal varicella vaccination on childhood varicella and herpes zoster hospitalizations in Brazil

    2018, Vaccine
    Citation Excerpt :

    The overall effectiveness of single dose varicella vaccine in preventing infection and severe disease is estimated to be 81 and 98%, respectively [6]. In a two doses schedule, the effectiveness against all forms of disease increases to more than 90%, with most of the data obtained from high-income countries, as United States of America, Australia, Germany, Italy, Spain and Canada [6–12]. In 2013, a tetraviral combined live and attenuated vaccine including measles, mumps, rubella and varicella (MMRV) was introduced in the Brazilian National Immunization Program (NIP), including all Brazilian states.

View all citing articles on Scopus
View full text